Because there is no point in asking questions if their results have no regulatory value, the IA & cancers Association has innovated by initiating a dialogue with the French National Authority for Health (HAS). Indeed, the mass of data is growing day by day and will redefine the potential of clinical research. Thus, it is important that the regulatory authorities acculturate and accompany these transformations so that they are beneficial to the creation of value and to patients. To do this, the IA & cancers Association shares with the French National Authority the study protocols of each of the projects carried out to :

• Explain the methods used in each project
• Document the issues addressed by the projects
• Benchmark practices on a European scale
• Qualify and quantify the potential impacts of the projects

The dialogue will lead to the publication of recommandations previously discussed with the French National Authority.